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systemic therapies available for the treatment of hepatocellular carcinoma, while also proposing a potential treatment algorithm.
The second article I would like to highlight is an editorial from Sean P Martin & Xin Wei Wang entitled 'The evolving landscape of precision medicine in primary liver cancer' [2] . It discusses current applications and potential inadequacies of precision medicine for the treatment of primary liver cancer, as well as examining whether precision medicine can result in improved outcomes.
Social media
Hepatic Oncology is active on social media and encourages our readers to follow us on twitter (@fsghep) in order to keep up to date with our latest content. We discuss the latest news and research surrounding liver cancer as well as our newly published articles. This platform allows us to engage with our readers and experts in the field alike.
Conclusion
Our readers are pivotal to the success of Hepatic Oncology and we are always seeking feedback to ensure the journal is the best it can be. Please do not hesitate to get in contact with any suggestions that you may have. We welcome a wide range of unsolicited article types, so please contact us if you are interested in submitting to the journal.
I would finally like to thank our authors, reviewers and editorial board for their hard work and continued support. I hope to build on the success of 2019 and am excited to see the continued development of the journal.
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